Pay in 4 interest-free payments of $6.18 Learn more
Ships within 48 hours · Estimated delivery Aug 31 - Sep 5
In landmark trials such as LEADER and SUSTAIN-6, liraglutide significantly lowered the risk of cardiovascular death, non-fatal myocardial infarction, and stroke by 13% compared to placebo ( 2 , 32% of whom also had type 2 diabetes
10.1016/S0140-6736(87)91194-9 78
QSC is not responsible for outcomes, interpretations, or conclusions drawn from any studies conducted using these products
Tirzepatide is an established, FDA-approved treatment with real-world outcomes, while Retatrutide remains investigational
The mazdutide versus retatrutide comparison is particularly relevant for those weighing triple agonist alternatives
US$ 23.47
US$ 28.68
US$ 26.32
US$ 28.55
US$ 27.28
US$ 25.76
US$ 20.22
US$ 25.12
